Glenmark Pharma.

July 2 (Reuters) - Glenmark Pharmaceuticals Ltd GLEN.NS:

• GLENMARK PHARMA - UNIT ADVANCES MULTI-COUNTRY PHASE 3 TRIAL FOR TRASTUZUMAB REZETECAN IN PLATINUM-RESISTANT OVARIAN CANCER

Source text: ID:nBSE55fTLy

Further company coverage: GLEN.NS

(([email protected];))

June 11 (Reuters) - Glenmark Pharmaceuticals Ltd GLEN.NS:

• GLENMARK PHARMA - LAUNCHES WINLEVI (CLASCOTERONE) 10 MG/G CREAM IN KEY EUROPEAN MARKETS

Source text: ID:nBSE1cHzrV

Further company coverage: GLEN.NS

(([email protected];;))

June 5 (Reuters) - Glenmark Pharmaceuticals Ltd GLEN.NS:

• GLENMARK PHARMA - GLENMARK PHARMACEUTICALS INC USA LAUNCHES LACOSAMIDE INJECTION USP

Source text: ID:nBSE7xtZqY

Further company coverage: GLEN.NS

(([email protected];))

May 29 (Reuters) - Glenmark Pharmaceuticals Ltd GLEN.NS:

• GLENMARK PHARMA Q4 CONSOL NET PROFIT 3.01 BILLION RUPEES

• GLENMARK PHARMA Q4 CONSOL NET SALES 37.6 BILLION RUPEES

• GLENMARK PHARMA - DECLARES DIVIDEND OF 2.5 RUPEES PER SHARE

Source text: [ID:]

Further company coverage: GLEN.NS

(([email protected];))

May 18 (Reuters) - Glenmark Pharmaceuticals Ltd GLEN.NS:

• GLENMARK PHARMA - LAUNCHES VANCOMYCIN HYDROCHLORIDE FOR INJECTION USP, 500 MG/VIAL AND 1 G/VIAL

Source text: ID:nBSE93bDRP

Further company coverage: GLEN.NS

(([email protected];))

April 9 (Reuters) - Glenmark Pharmaceuticals Ltd GLEN.NS:

• RECEIVES U.S. FDA APPROVAL FOR PROGESTERONE VAGINAL INSERTS, 100 MG

Source text: ID:nNSE8j4qcP

Further company coverage: GLEN.NS

(([email protected];))

April 1 (Reuters) - Glenmark Pharmaceuticals Ltd GLEN.NS:

• GLENMARK PHARMA - TO DIRECTLY COMMERCIALIZE AND DISTRIBUTE RYALTRIS IN U.S. EFFECTIVE APRIL 1, 2026

Source text: ID:nBSE33lGVw

Further company coverage: GLEN.NS

(([email protected];))

SHANGHAI, March 25 (Reuters) - Jiangsu Hengrui Pharmaceuticals 600276.SS, China's biggest drugmaker by market value, reported fourth-quarter profit below market expectations on Wednesday, as income from business development deals has failed to appear.

The specialist in oncology, neurology, immunology, respiratory, metabolic and cardiovascular drugs has expanded licensing deals and developed more innovative drugs amid Beijing's centralised bulk buying programmes, which have squeezed generic drug revenues.

In September, Hengrui agreed to grant a paid licence for its innovative cancer drug, trastuzumab rezetecan, to the Swiss arm of India's Glenmark Pharmaceuticals GLEN.NS, with an upfront payment of $18 million under the deal.

The deal was a part of a string of new licensing agreements earlier last year with overseas drugmakers such as Merck MRK.N and Britain's GSK GSK.L.

Hengrui's revenue from innovative drug sales increased 26.09% in 2025 but revenue from generic drug slipped, it said in its annual report.

The company recorded 1.96 billion yuan ($284.10 million) in net profit attributable to shareholders for the quarter ended December 31, its annual report showed, below HSBC Qianhai Securities analysts' estimate of 2.7 billion yuan.

Net profit for the entire 2025 rose 21.69% to 7.71 billion yuan.

($1 = 6.8989 Chinese yuan renminbi)

(Reporting by Andrew Silver, Editing by Louise Heavens)

March 23 (Reuters) - At least half a dozen Indian generic drugmakers launched cheaper versions of Novo Nordisk's NOVOb.CO blockbuster diabetes drug Ozempic and weight‑loss drug Wegovy over the weekend, at globally unmatched prices and slashing treatment costs by about 70%.

The patent for semaglutide, the active ingredient in Novo's drugs, expired in India last week, paving the way for drugmakers to flood the market with dozens of brands.

Analysts expect more than 40 Indian drugmakers to launch over 50 cheaper variants.

Large Indian drugmakers are racing to capture a share of the global obesity market, projected to be worth about $100 billion by the end of the decade. They are eyeing overseas markets, including Canada, Brazil, Latin America, and Turkey, for future launches.

Here is a list of Indian drugmakers that have launched generic semaglutide in recent days:

SUN PHARMACEUTICAL SUN.NS

India's largest drugmaker by revenue launched semaglutide injectable under the brand name Noveltreat for chronic weight management in five dose strengths from 0.25 mg to 2.4 mg and Sematrinity in two dose strengths for type 2 diabetes. Noveltreat is expected to cost around 900 to 2000 rupees ($9.58-$21.30) for weekly treatment, and Sematrinity will cost 750 to 1300 rupees ($7.99-$13.84), the company said.

DR REDDY'S LABORATORIES REDY.NS

The Hyderabad-based drugmaker launched semaglutide under the brand name Obeda for diabetes in 2 mg and 4 mg dose strengths in a disposable pen device format. Each pen of both strengths will deliver a minimum of four weekly doses and cost about 4200 rupees ($44.73) per month, the company said.

ZYDUS LIFESCIENCES ZYDU.NS

The company launched generic injectable semaglutide under three different brand names- Semaglyn, Mashema, and Alterme - for diabetes and obesity treatment in a reusable pen device. The average monthly cost of the treatment will be approximately 2,200 rupees ($23.43), the company said.

TORRENT PHARMACEUTICALS TORP.NS

The company launched an oral and injectable semaglutide drug under the brand names Sembolic and Semalix. The starting price for the injectable drugs would be 3,999 rupees ($42.59) per month, the company said.

GLENMARK PHARMACEUTICALS GLEN.NS

Glenmark launched injectable semaglutide, branded as GLIPIQ, in vial and pen formats for diabetes treatment. The vial is estimated to cost around 1,300 to 1,760 rupees for a month's usage. ($13.84-$18.74).

ALKEM LABORATORIES ALKE.NS

The company said its semaglutide, launched under three brand names - Semasize, Obesema, and Hepaglide - will be available in a pre-filled disposable injection pen and cost starting at 1,800 rupees ($19.17) per month.

ERIS LIFESCIENCES ERIS.NS

The company launched generic semaglutide in a vial format named 'Sundae.' The starting price for the multi-dose vials is 1,290 rupees ($13.74) per month. Eris is also in partnership with Natco Pharma NATP.NS, which has also launched its own generic semaglutide, for commercial manufacturing of the drug.

($1 = 93.9000 Indian rupees)

(Reporting by Rishika Sadam; Editing by Rashmi Aich)

(([email protected];))

March 4 (Reuters) - Glenmark Pharmaceuticals Ltd GLEN.NS:

• GLENMARK SPECIALTY SA RECEIVES U.S. FDA APPROVAL FOR FLUTICASONE PROPIONATE INHALATION AEROSOL USP, 44 MCG PER ACTUATION, WITH 180-DAY COMPETITIVE GENERIC THERAPY EXCLUSIVITY

• GLENMARK PHARMA - TO DISTRIBUTE FLUTICASONE PROPIONATE INHALATION AEROSOL IN U.S. STARTING MARCH 2026

Source text: ID:nPn2YYB0ka

Further company coverage: GLEN.NS

(([email protected];))

Feb 27 (Reuters) - Glenmark Pharmaceuticals Ltd GLEN.NS:

• TO LAUNCH SODIUM PHOSPHATES INJECTION IN USA

• SODIUM PHOSPHATES INJECTION DISTRIBUTION TO BEGIN IN APRIL 2026

Source text: ID:nNSE1w4VMD

Further company coverage: GLEN.NS

(([email protected];;))

Jan 30 (Reuters) - Glenmark Pharmaceuticals Ltd GLEN.NS:

• GLENMARK PHARMA Q3 CONSOL NET PROFIT 4.03 BILLION RUPEES

• GLENMARK PHARMA Q3 CONSOL TOTAL REVENUE FROM OPERATIONS 39.01 BILLION RUPEES

Source text: [ID:]

Further company coverage: GLEN.NS

(([email protected];))

** Shares of Glenmark Pharma GLEN.NS rise 2.8% to 2,047.3 rupees, their highest in over 3 weeks

** Drugmaker starts phase 3 trial of cancer drug Envafolimab in India after drug regulator's nod

** Company says clinical trial applications are underway in Russia, Brazil, and Mexico

** Stock rated "buy" on avg; median PT is 2,380 rupees - data compiled by LSEG

** Stock up 27.3% YTD

(Reporting by Aleef Jahan in Bengaluru)

(([email protected]))

** Shares of Glenmark Pharmaceuticals GLEN.NS up 3.5% to 1985 rupees

** HSBC Global Investment Research retains "buy" rating and PT of 2,380 rupees ($27.20) on GLEN on the back of good visibility on growth drivers

** Easing R&D spend, start of supplies from Monroe plant, U.S. FDA approval for gFlovent, pick-up in the U.S. and India businesses led by new launches are key drivers for GLEN's growth - HSBC

** Stock set to rise most in a session since July 11

** Stock has been above its 100-day, 200-day simple moving avgs since June, indicating bullish sentiment

** Avg rating of nine analysts is "buy" and median PT is 2,380 rupees, ~19% higher than current price - data compiled by LSEG

** YTD, GLEN up ~24%

($1 = 87.5060 Indian rupees)

(Reporting by Anuran Sadhu in Bengaluru)

(([email protected]; +91 8697274436;))

Sept 2 (Reuters) - Glenmark Pharmaceuticals GLEN.NS:

• TO LAUNCH ERIBULIN MESYLATE INJECTION IN USA

• TO BEGIN DISTRIBUTION IN SEPTEMBER 2025

Source text: ID:nBSE5B7S0j

Further company coverage: GLEN.NS

(([email protected];))

Aug 19 (Reuters) - Glenmark Pharmaceuticals Ltd GLEN.NS:

• GLENMARK PHARMACEUTICALS INC TO LAUNCH MICAFUNGIN FOR INJECTION USP

Source text: ID:nnAZN4DSC95

Further company coverage: GLEN.NS

(([email protected];;))

** Shares of Glenmark Pharma GLEN.NS fall 1.45% to 2,014.9 rupees

** Drugmaker's Q1 consol PBT fell 9% to 4.19 bln rupees ($47.96 million), net sales down by 5% at 30.59 bln rupees hit by pricing pressure in North America and Europe

** Sales in North America slipped 0.4%, while that in Europe dropped 4% for the quarter

** Europe and Emerging markets businesses to deliver a double-digit growth from Q2 onwards, chairman says

** 9 analysts covering GLEN have a "buy" rating on average, median PT is 2,365 rupees - data compiled by LSEG

** Stock up ~25% YTD

($1 = 87.3675 Indian rupees)

(Reporting by Urvi Dugar)

(([email protected]))

Aug 14 (Reuters) - Glenmark Pharmaceuticals Ltd GLEN.NS:

• APPROVES TRANSFER OF CONSUMER CARE BUSINESS TO SUBSIDIARY

• BUSINESS TRANSFER VALUED AT 2.40 BILLION RUPEES

Source text: ID:nBSE9HGC1t

Further company coverage: GLEN.NS

(([email protected];))

Corrects to add "treatment" in headline

July 11 (Reuters) - Shares of Glenmark Pharmaceuticals GLEN.NS jumped 10% in early trade on Friday, a day after a unit of the Indian drugmaker signed an exclusive licensing deal with U.S. peer AbbVie ABBV.N for its cancer treatment.

(Reporting by Hritam Mukherjee in Bengaluru; Editing by Sonia Cheema)

(([email protected]; X: @MukherjeeHritam;))

July 10 (Reuters) - Glenmark Pharmaceuticals Ltd GLEN.NS:

• ICHNOS GLENMARK INNOVATION (IGI) AND ABBVIE ANNOUNCE EXCLUSIVE GLOBAL LICENSING AGREEMENT

• LICENSING AGREEMENT FOR ISB 2001

• IGI WILL RECEIVE AN UPFRONT PAYMENT OF $700 MILLION, ELIGIBLE TO RECEIVE UP TO $1.225 BILLION

Source text: ID:nBSE3Lp8jW

Further company coverage: GLEN.NS

(([email protected];))

June 18 (Reuters) - Glenmark Pharmaceuticals Ltd GLEN.NS:

• U.S. FDA INSPECTION AT THE COMPANY'S FACILITY AT MONROE, NORTH CAROLINA, USA

• COMPANY WAS ISSUED A FORM 483 WITH FIVE OBSERVATIONS BY USFDA

• OBSERVATIONS ARE PROCEDURAL IN NATURE

• THERE WAS NO OBSERVATION RELATED TO DATA INTEGRITY REPORTED

Source text: [ID:]

Further company coverage: GLEN.NS

(([email protected];;))

June 9 (Reuters) - Glenmark Pharmaceuticals Ltd GLEN.NS:

• TO LAUNCH DCGI-APPROVED ZANUBRUTINIB IN INDIA

• ZANUBRUTINIB TO BE MARKETED AS BRUKINSA IN INDIA

Source text: ID:nBSE95v3F3

Further company coverage: GLEN.NS

(([email protected];;))

May 12 (Reuters) - Indian pharmaceutical stocks .NIPHARM shed 1.3% on Monday, even as the broader markets rose, after U.S. President Donald Trump said he would sign an executive order to cut prescription prices to the level paid by other high-income countries, an amount he put at 30% to 80% less.

Eight of the 20 stocks on the pharmaceutical sub-index were in the red, while the benchmark Nifty 50 index .NSEI was trading 2.4% higher.

Sun Pharma, India's top drugmaker by revenue, dropped 5.4% to be the top loser on the Nifty 50 and the pharma index. Glenmark Pharma GLEN.NS and Cipla CIPL.NS declined 0.4% and 1.5%, respectively.

Trump said he would sign the executive order on Monday morning to pursue what is known as "most favored nation" pricing or international reference pricing.

The U.S. pays the most in the world for many prescription drugs, often nearly triple that of other developed nations. Trump has said he wants to close that spread, but has not publicly specified how and did not provide details.

Several Indian drugmakers get a significant chunk of their revenue from North America by selling cheaper versions of the latest drugs.

The U.S. imports nearly a third of Indian pharma products sold overseas.

India's pharma exports to the U.S. jumped 16% to about $9 billion last fiscal year, according to data from government-backed trade body Pharmexcil.

(Reporting by Kashish Tandon in Bengaluru; Editing by Mrigank Dhaniwala)

(([email protected]; 8800437922;))

May 5 (Reuters) - Glenmark Pharmaceuticals Ltd GLEN.NS:

• GLENMARK PHARMACEUTICALS LTD - IGI RECEIVES FDA FAST TRACK DESIGNATION FOR ISB 2001

Source text: ID:nBSE1SYXkx

Further company coverage: GLEN.NS

(([email protected];;))

April 29 (Reuters) - Glenmark Pharmaceuticals Ltd GLEN.NS:

• CLAIRIFIES REPORT ABOUT CDSCO FLAGGING DRUGS

• PRODUCTS REFERRED TO IN REPORT SPURIOUS; NOT MADE BY CO

Source text: ID:nnAZN3RNEEN

Further company coverage: GLEN.NS

(([email protected];;))

April 16 (Reuters) - Glenmark Pharmaceuticals Ltd GLEN.NS:

• GLENMARK PHARMA - GLENMARK PHARMACEUTICALS INC., USA TO LAUNCH DEXTROAMPHETAMINE SACCHARATE TABLETS

• GLENMARK PHARMA-GLENMARK PHARMA INC TO LAUNCH MIXED SALTS OF SINGLE ENTITY AMPHETAMINE PRODUCT TABLETS

Further company coverage: GLEN.NS

(([email protected];))

April 9 (Reuters) - Indian pharmaceutical stocks .NIPHARM fell 1.7% on Wednesday after U.S. President Donald Trump reiterated plans to announce a "major" tariff on all pharmaceutical imports.

U.S. accounts for a third of India's overall pharma exports.

Trump also threatened the duties on Friday, after his first set of reciprocal tariffs earlier last week exempted pharma products -- a change in stance that had prompted a wild swing in pharma stocks.

On the day, all twenty constituents of the pharma index were lower, with the index dragging down the benchmark Nifty 50 .NSEI by about 0.52% as of 9:20 a.m. IST.

Gland Pharma GLAD.NS, Lupin LUPN.NS and Zydus Lifesciences ZYDU.NS were the top losers by percentage, down between 3% and 5%.

Sun Pharma SUN.NS and Cipla CIPL.NS, the top constituents by weight, fell 1.69% and 1.87%, respectively.

India's pharma exports to the U.S. mostly comprise generics, or cheaper versions of popular drugs. These currently attract almost no U.S. levies, while India imposes about 10% tax on U.S. pharma imports, according to industry experts.

The pharma index has fallen 14.4% this year.

(Reporting by Kashish Tandon and Ananta Agarwal in Bengaluru; Editing by Savio D'Souza)

(([email protected];))